They comprise seven antitumor agents, including ripretinib, a multikinase inhibitor, trastuzumab deruxtecan, a conjugate of an anti-HER2/neu antibody with a cytostatic agent, and tebentafusp, a fusion protein directed against gp100 of melanoma cells plus CD3 of T cells; drugs are indicated for advanced gastrointestinal stromal tumor, breast cancer, and uveal melanoma, respectively. The gene discussed is PMEL; the disease is uveal melanoma.